Dare bioscience, inc. (DARE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

766

-

-

-

-

-

-

-

0

0

33

47

6

-

-

-

Operating expenses
General and administrative

1,861

1,361

1,318

1,307

1,277

1,020

1,175

1,157

1,303

975

1,052

476

200

2,090

5

117

3,118

2,872

2,954

2,717

2,681

2,607

2,441

2,029

1,510

1,575

1,227

1,392

1,972

Research and development

2,379

2,373

1,966

2,512

1,693

1,663

1,446

2,217

1,086

672

280

3

27

3,184

-

-

9,770

7,157

7,092

6,678

5,021

4,701

2,928

2,648

1,495

1,440

1,586

3,195

3,479

License Fee

12

125

133

162

112

275

0

250

100

-

-

-

-

-

-

250

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

-

-

0

0

-

-12

0

0

5,200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

4,254

3,860

3,418

3,982

3,083

2,958

2,621

3,624

7,677

9,138

1,333

479

228

5,274

5

367

12,888

10,029

10,046

9,395

7,702

7,308

5,369

4,677

3,005

3,015

2,813

4,587

5,451

Loss from operations

-4,254

-3,860

-3,418

-3,982

-3,083

-2,958

-2,621

-3,624

-7,677

-9,138

-1,333

-479

-228

-

-5

-367

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income (expense)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

20

-

-

16

2

4

1

3

4

2

2

1

1

0

0

1

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

457

-

-

670

689

509

513

721

163

191

268

461

430

378

326

353

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,493

-

-

-

-

-

Decrease in value of preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-504

42

7

-20

-231

Other income

1

-5

25

30

31

42

47

42

11

7

-296

-18

-15

-

-

-

-

-

-

-

-

-

-

-

-

-471

-385

-306

-121

Total other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-437

-

-

-654

-687

-505

-512

-718

-159

-189

-2,759

44

-

-

-

-

Net loss

-4,252

-3,866

-3,393

-3,952

-3,051

-2,916

-2,574

-3,582

-7,665

-9,131

-1,629

-498

-243

-4,945

-16

-367

-13,542

-10,716

-10,551

-9,907

-8,420

-7,467

-5,558

-7,403

-2,914

-

-

-

-

Deemed dividend from trigger of round down provision feature

-

-

0

789

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss to common shareholders

-

-

-3,393

-4,742

-

-

-2,574

-3,582

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,480

-3,198

-4,893

-5,572

Foreign currency translation adjustments

-22

9

-15

-7

7

-18

-18

-27

-13

-

-9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-4,275

-3,856

-3,408

-4,749

-3,044

-2,935

-2,593

-3,609

-7,679

-9,139

-1,639

-498

-243

-

-16

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss per common share - basic and diluted (in usd per share)

-0.18

-0.21

-0.20

-0.29

-0.27

-0.14

-0.23

-0.32

-0.88

4.71

-0.33

-0.55

-0.27

-0.17

-0.02

-

-0.49

-0.39

-0.39

-0.37

-0.41

-0.37

-0.28

-0.44

-3.70

-4.45

-4.40

-7.96

-9.09

Weighted average number of common shares outstanding:
Basic

-

-

-

-

-

-

-

-

-

-

-

910

910

-

820

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

830

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted (in shares)

23,799

18,105

16,683

16,105

11,422

11,400

11,422

11,422

8,684

-

4,986

-

-

28,724

-

-

27,362

27,346

27,307

26,690

20,350

20,125

20,124

16,883

786

782

726

614

612